Unichem Labs.
Drug Manufacturers - Specialty & Generic · UNICHEMLAB
Small CapHealthcareDistressed / Turnaround
Pabitrakumar Bhattacharyya
Managing Director · Pragmatic
Company DNA
Hierarchical
About
Unichem Labs. is a Small Cap company in the Healthcare sector, listed on NSE as UNICHEMLAB. With a market cap of ₹2K Cr and revenue of ₹2K Cr, it is currently in the Distressed / Turnaround phase. Known for its Hierarchical culture and Traditionalist approach to innovation, the company operates at a Steady-Marathon pace. Legacy pharma business undergoing turnaround; structure remains formal and process-driven typical of established manufacturing entities. Its strategic mandate: Following recent acquisition activity and legacy challenges, the company requires a mandate to stabilize finances and streamline the portfolio.
FAQ
What kind of company is Unichem Labs.?
Unichem Labs. is a Small Cap Healthcare company (UNICHEMLAB) in the Distressed / Turnaround phase with a market cap of ₹2K Cr. It is classified as Hierarchical in culture.
What is Unichem Labs.'s culture and work environment like?
Unichem Labs. has a Hierarchical culture with Traditionalist innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. Legacy pharma business undergoing turnaround; structure remains formal and process-driven typical of established manufacturing entities.
Who leads Unichem Labs.?
Unichem Labs. is led by Pabitrakumar Bhattacharyya (Managing Director), a Pragmatic leader with 30 years of experience.
What are Unichem Labs.'s financials?
Unichem Labs. reported revenue of ₹2K Cr in FY25 with a 5-year revenue CAGR of 18.3%. Operating margin: 6.8%. Market cap: ₹2K Cr.
Culture & Strategy
CultureHierarchical
InnovationTraditionalist
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandValue-Champion
LifecycleDistressed / Turnaround
Legacy pharma business undergoing turnaround; structure remains formal and process-driven typical of established manufacturing entities.
Mandate
Following recent acquisition activity and legacy challenges, the company requires a mandate to stabilize finances and streamline the portfolio.
Following recent acquisition activity and legacy challenges, the company requires a mandate to stabilize finances and streamline the portfolio.
Financials
Revenue FY25₹2K Cr
PAT FY25₹138 Cr
Rev CAGR 5Y18.3%
OPM6.8%
NPM6.7%
ROE5.6%
ROCE5.4%
P/E7.7
Fwd P/E—
P/B0.9
D/E20.6
Mkt Cap₹2K Cr
Promoter71.3%
Institutional10%
Similar Culture
Could You Lead Unichem Labs.?
Take the Genome Benchmark →